SIONNA THERAPEUTICS INC

SIONNASDAQ

🏆 #3015 by market capEarnings Nov 4US Equity

$192.95▲ $13.10 (+6.79%)

Simulated price

1h—

24h▲ 6.8%

7d▲ 307.2%

14d▲ 330.9%

30d▲ 339.7%

1y▲ 820.3%

🏦Market Cap

$203M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $191.10 – $195.62
52-Week Range: $4.01 – $54.97
Volume: $2.32B
Avg Volume: $2.16B
Shares Outstanding: 45.1M
Next Earnings: Sep 11, 2026

Fundamentals Snapshot

Annual Revenue: $19M
Last Q Revenue: $5M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.92
Dividend Yield: —

Why Investors Own SION

✓High-growth profile — revenue up +46.1% YoY with expanding US Equity exposure.
✓Healthy economics — 36% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$19M▲ +48.1% YoY

Gross Margin (TTM)

35.7%▲ +1.0% YoY

Operating Income (TTM)

$5M▲ +48.1% YoY

Free Cash Flow (TTM)

$3M▲ +48.1% YoY

About SIONNA THERAPEUTICS INC

Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.

🦦